The effects of lithium and anticonvulsants on brain structure in bipolar disorder

Acta Psychiatrica Scandinavica

Volumn 122, Issue 6, 2010, Pages 481-487

  Germana C ^a,b   Kempton, M J ^a   Sarnicola, A ^a,b   Christodoulou, T ^a   Haldane, M ^a   Hadjulis, M ^a   Girardi, P ^b   Tatarelli, R ^b   Frangou, S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Affective disorders; Neuroimaging; Psychopharmacology

Indexed keywords

ANTICONVULSIVE AGENT; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; AMYGDALOID NUCLEUS; ARTICLE; BIPOLAR DISORDER; BRAIN; BRAIN REGION; BRAIN SIZE; CEREBROSPINAL FLUID ANALYSIS; CINGULATE GYRUS; DRUG EFFECT; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; INSULA; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; WHITE MATTER;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ANTIMANIC AGENTS; BIPOLAR DISORDER; BRAIN; BRAIN MAPPING; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LITHIUM; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 78149384661     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/j.1600-0447.2010.01582.x     Document Type: Article

References (47)

1. NICE. The National Institute for Health and Clinical Excellence. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline No. 38. London: NICE, 2006.
2. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 1998;95:2642-2647.
3. Chuang DM. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005;1053:195-204.
4. Angelucci F, Aloe L, Jimenez-Vasquez P, Mathe AA. Lithium treatment alters brain concentrations of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor in a rat model of depression. Int J Neuropsychopharmacol 2003;6:225-231.
5. Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem 2000;75:1729-1734.
6. Hashimoto R, Senatorov V, Kanai H, Leeds P, Chuang DM. Lithium stimulates progenitor proliferation in cultured brain neurons. Neuroscience 2003;117:55-61.
7. Silverstone PH, Wu RH, O'donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. Int Clin Psychopharmacol 2003;18:73-79.
8. Sharma R, Venkatasubramanian PN, Barany M, Davis JM. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients. Schizophr Res 1992;8:43-49.
9. Bearden CE, Thompson PM, Dalwani M et al. Greater cortical gray matter density in lithium-treated patients with bipolar disorder. Biol Psychiatry 2007;62:7-16.
10. Foland LC, Altshuler LL, Sugar CA et al. Increased volume of the amygdala and hippocampus in bipolar patients treated with lithium. Neuroreport 2008;19:221-224.
11. Yucel K, Mckinnon MC, Taylor VH et al. Bilateral hippocampal volume increases after long-term lithium treatment in patients with bipolar disorder: a longitudinal MRI study. Psychopharmacology 2007;195:357-367.
12. Yucel K, Taylor VH, Mckinnon MC et al. Bilateral hippocampal volume increase in patients with bipolar disorder and short-term lithium treatment. Neuropsychopharmacology 2008;33:361-367.
13. Savitz J, Nugent AC, Bogers W et al. Amygdala volume in depressed patients with bipolar disorder assessed using high resolution 3T MRI: the impact of medication. Neuroimage 2010;4:2966-2976.
14. Usher J, Menzel P, Schneider-Axmann T et al. Increased right amygdala volume in lithium-treated patients with bipolar I disorder. Acta Psychiatr Scand 2010;121:119-124.
15. Moore GJ, Bebchuk JM, Wilds IB, Chen G, Manji HK. Lithium-induced increase in human brain grey matter. Lancet 2000;356:1241-1242.
16. Sassi RB, Nicoletti M, Brambilla P et al. Increased gray matter volume in lithium-treated bipolar disorder patients. Neurosci Lett 2002;329:243-245.
17. Penttilä J, Paillère-Martinot ML, Martinot JL et al. Cortical folding in patients with bipolar disorder or unipolar depression. J Neuropsychiatry Clin Neurosci 2009;34:127-135.
18. Atmaca M, Ozdemir H, Cetinkaya S et al. Cingulate gyrus volumetry in drug free bipolar patients and patients treated with valproate or valproate and quetiapine. J Psychiatr Res 2007;41:821-827.
19. Atmaca M, Yildirim H, Ozdemir H, Ogur E, Tezcan E. Hippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine. Psychol Med 2007;37:121-129.
20. Lieberman JA, Tollefson GD, Charles C et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005;62:361-370.
21. Li XM, Xu H. Evidence for neuroprotective effects of antipsychotic drugs: implications for the pathophysiology and treatment of schizophrenia. Int Rev Neurobiol 2007;77:107-142.
22. Dazzan P, Morgan KD, Orr K et al. Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study. Neuropsychopharmacology 2005;30:765-774.
23. Jarskog LF. Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations. Curr Opin Psychiatry 2006;19:307-312.
24. Delbello MP, Cecil KM, Adler CM, Daniels JP, Strakowski SM. Neurochemical effects of olanzapine in first-hospitalization manic adolescents: a proton magnetic resonance spectroscopy study. Neuropsychopharmacology 2006;31:1264-1273.
25. Donaldson S, Goldstein LH, Landau S, Raymont V, Frangou S. The Maudsley Bipolar Disorder Project: the effect of medication, family history, and duration of illness on IQ and memory in bipolar I disorder. J Clin Psychiatry 2003;64:86-93.
26. Frangou S, Raymont V, Bettany D. The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disord 2002;4:378-385.
27. Haldane M, Cunningham G, Androutsos C, Frangou S. Structural brain correlates of response inhibition in Bipolar Disorder I. J Psychopharmacol 2008;22:138-143.
28. Raymont V, Bettany D, Frangou S. The Maudsley bipolar disorder project. Clinical characteristics of bipolar disorder I in a Catchment area treatment sample. Eur Psychiatry 2003;18:13-17.
29. Frangou S, Haldane M, Roddy D, Kumari V. Evidence for deficit in tasks of ventral, but not dorsal, prefrontal executive function as an endophenotypic marker for bipolar disorder. Biol Psychiatry 2005;58:838-839.
30. Frangou S. Risk and resilience in Bipolar Disorder: rationale and design of the Vulnerability to Bipolar Disorders study (VIBES). Biochem Soc Trans 2009;37:1085-1089.
31. APA. Diagnostic and statistical manual of mental disorders. 4th edn. Washington: American Psychiatric Association, 1994.
32. First MBSR, Gibbon M, Williams J. Structured clinical interview for DSM-IV axis I disorders - patient edition (SCID-I/P) version 2.0. New York: Biometrics Research Department, New York State Psychiatric Institute, 1996.
33. Wechsler DW. Wechsler adult intelligence scale-revised (WAIS-R) manual. New York: Psychological Corporation, 1981.
34. Ashburner J, Friston KJ. Unified segmentation. Neuroimage 2005;26:839-851.
35. Cohen J. Statistical power analysis for the behavioural sciences. New York: New York Academic Press, 1969.
36. Scherk H, Kemmer C, Usher J et al. No change to grey and white matter volumes in bipolar I disorder patients. Eur Arch Psychiatry Clin Neurosci 2008;258:345-349.
37. Nery FG, Chen HH, Hatch JP et al. Orbitofrontal cortex gray matter volumes in bipolar disorder patients: a region-of-interest MRI study. Bipolar Disord 2009;11:145-153.
38. Monkul ES, Matsuo K, Nicoletti MA et al. Prefrontal gray matter increases in healthy individuals after lithium treatment: a voxel-based morphometry study. Neurosci Lett 2007;429:7-11.
39. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000;48:740-754.
40. Colla M, Schubert F, Bubner M et al. Glutamate as a spectroscopic marker of hippocampal structural plasticity is elevated in long-term euthymic bipolar patients on chronic lithium therapy and correlates inversely with diurnal cortisol. Mol Psychiatry 2009;14:696-704.
41. Kessing LV, Sondergard L, Forman JL et al. Lithium treatment and risk of dementia. Arch Gen Psychiatry 2008;65:1331-1335.
42. Orre K, Wennström M, Tingström A. Chronic lithium treatment decreases NG2 cell proliferation in rat dentate hilus, amygdala and corpus callosum. Prog Neuropsychopharmacol Biol Psychiatry 2009;33:503-510.
43. Chen PS, Peng GS, Li G et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006;11:1116-1125.
44. Wilot LC, Bernardi A, Frozza RL et al. Lithium and valproate protect hippocampal slices against ATP-induced cell death. Neurochem Res 2007;32:1539-1546.
45. Michoulas A, Tong V, Teng XW, Chang TK, Abbott FS, Farrell K. Oxidative stress in children receiving valproic acid. J Paediatr 2006;149:692-696.
46. Jamora D, Lim SH, Pan A, Tan L, Tan EK. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord 2007;22:130-133.
47. Regenold WT. Lithium and increased hippocampal volume-more tissue or more water? Neuropsychopharmacology 2008;33:1773-1774.